Project Grant R41CA247025

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $605,314 to the Icahn School of Medicine at Mount Sinai to investigate the efficacy of G-tocotrienol for the prevention of post-partum breast cancer. The 5-year project aims to: 1) establish the most effective regimen for administering G-tocotrienol to prevent post-partum breast cancer, 2) investigate the protective effect of G-tocotrienol on late pregnancy in older mice, and...

This Project Grant award, valued at $150,701.00 and provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), aims to investigate the relationship between diet, gut microbiome, and cancer treatment-related cognitive impairment (CRCI) in breast cancer survivors (BCS) undergoing chemotherapy. The key objectives are to: 1) determine the relationship between components of a Mediterranean diet, gut microbiome, and cognitive function in 30 BCS before, during, and...

This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding of $179,988 to the University of Utah to conduct research on the role of dietary lipids in accelerating breast cancer tumor growth, particularly in the context of obesity. The key objectives are to: Determine if breast cancer cells preferentially utilize dietary lipids over glucose in lipid-rich environments, such as those found in obesity. Trace the metabolic fate of...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $798,512 to Luminary Therapeutics, Inc. to develop an allogeneic gamma/delta armored dual-targeting chimeric antigen receptor (CAR) T-cell therapy to treat epithelial ovarian carcinoma. The project aims to address key challenges with current CAR T-cell therapies against solid tumors, including antigen escape and poor T-cell persistence, by using a "split CAR" approach that...

This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $678,399 to The University of Texas MD Anderson Cancer Center to conduct a prebiotic diet intervention study. The goal is to evaluate whether a prebiotic-enriched diet can enhance the gut microbiome and improve response to immune checkpoint inhibitor (ICI) therapy in patients with metastatic melanoma. The 5-year study will investigate the...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $349,808 to Oncurie Inc. to continue development of a novel targeted radiopharmaceutical for imaging and potential therapy of ovarian cancer. The compound leverages the folate receptor overexpression in ovarian tumors to enable precision imaging, with future plans to incorporate cytotoxic radionuclides for targeted therapy. During the Phase I award period from Sep 2024...

The National Cancer Institute (NCI) awarded a 5-year, $564,695 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Texas MD Anderson Cancer Center to study a new driver and therapeutic vulnerability of bone metastasis. The research aims to investigate the role of acyl-CoA binding protein (ACBP) in regulating lipid metabolism and promoting breast cancer bone metastasis. Specifically, the project will examine how ACBP stimulates fatty acid oxidation and protects against...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Toledo's Health Science Campus Division aims to investigate the molecular basis of fatty acid synthase (FASN) and its role in overcoming resistance to PARP inhibitors (PARPi) in triple-negative breast cancer (TNBC). The $524,419 award, effective February 1, 2025 through January 31, 2030, will pursue three specific aims: 1) determine the molecular mechanism of PPI...

This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $713,235 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to conduct a randomized controlled trial evaluating the efficacy of the MIND diet in improving cognitive function among breast cancer survivors experiencing cancer-related cognitive impairment. The 5-year project will enroll 200 breast cancer survivors and assess the impact of the...

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Northwestern University provides $187,000.00 in funding from March 10, 2025 to February 28, 2027. The grant supports research to investigate how lipid metabolism and epigenetic reprogramming in breast tissue may contribute to the development of estrogen receptor-negative breast cancer. Key objectives include exploring the expression of neural genes, identifying histone...